Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 8:14:70.
doi: 10.1186/s12957-016-0832-6.

Downregulation of selenium-binding protein 1 is associated with poor prognosis in lung squamous cell carcinoma

Xing Tan  1 , Li Liao  2 , Yan-Ping Wan  3 , Mei-Xiang Li  4 , Si-Han Chen  5 , Wen-Juan Mo  6 , Qiong-Lan Zhao  7 , Li-Fang Huang  8 , Gu-Qing Zeng  9
Affiliations

Downregulation of selenium-binding protein 1 is associated with poor prognosis in lung squamous cell carcinoma

Xing Tan et al. World J Surg Oncol. .

Abstract

Background: We found that selenium-binding protein 1 (SBP1) was progressively decreased in the human bronchial epithelial carcinogenic processes. Knockdown of SBP1 in immortalized human bronchial epithelial cell line 16HBE cells significantly increased the efficiency of B[a]P-induced cell transformation. However, the relationship between SBP1 expression and clinicopathological factors of patients has not been defined completely. The specific role of SBP1 in prognosis of lung squamous cell carcinoma (LSCC) is still unknown.

Methods: Tissue samples from 82 patients treated by pulmonary lobectomy for LSCC were used. Immunohistochemistry and western blotting were used to detect the expressions of SBP1 protein. The relationships between the expression level of SBP1 and the clinicopathological features of patients were analyzed. Cox proportional hazard regression analysis and Kaplan-Meier method were used to perform survival analysis.

Results: Expressions of SBP1 proteins were significantly lower in LSCC tissues than that in the corresponding normal bronchial epithelium (NBE) tissues (P = 0.000). In LSCC, The expression levels of SBP1 had not correlated with patients' age, gender, smoking state, primary tumor stages (T), TNM clinical stages, and distant metastasis (M) (P > 0.05). However, downregulation of SBP1 was significantly associated with higher lymph node metastasis and lower overall survival rate (P < 0.05). Cox regression analysis indicated low expressions of SBP1 can be an independent prognostic factor for poor overall survival in LSCC patients (P = 0.002).

Conclusions: Downregulation of SBP1 may play a key role in the tumorigenic process of LSCC. SBP1 may be a novel potential prognostic factor of LSCC.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Purification of human normal bronchial epithelium and lung squamous cell carcinoma tissues by LCM. a H.E. staining of NBE (a), NBE before (b) and after (c) LCM, and captured NBE cells (d). b H.E. staining of LSCC (a), LSCC before (b) and after (c) LCM, and captured LSCC cells (d)
Fig. 2
Fig. 2
Expression of SBP1 in the human normal bronchial epithelium and lung squamous cell carcinoma tissues. a A representative result of immunohistochemistry shows expression of SBP1 is reduced in LSCC compared with the matched NBE. Original magnification, ×200. b A representative result of western blotting shows the expressions of SBP1 in the microdissected NBE and LSCC; c histogram shows the expression levels of SBP1 in NBE and LSCC tissues as determined by densitometric analysis. β-Actin is used as the internal loading control. Columns, mean from 16 cases of tissues; bars, SD (*P < 0.05 by one-way ANOVA)
Fig. 3
Fig. 3
Kaplan–Meier survival plots for LSCC patients according to the expression levels of SBP1. SBP1 expression and overall survival (P = 0.000). P value was determined using a two-sided log-rank test
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Wen C, Dehnel T. China wrestles with lung cancer. Lancet Oncol. 2011;12(1):15. doi: 10.1016/S1470-2045(10)70303-X. - DOI - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, et al. Suitability of EBUS-TBNA specimens for subtyping and genotyping of NSCLC: a multi-center study of 774 patients. Am J Respir Crit Care Med. 2012;185(12):1316–22. doi: 10.1164/rccm.201202-0294OC. - DOI - PMC - PubMed
    1. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93(11):824–42. doi: 10.1093/jnci/93.11.824. - DOI - PubMed

Publication types

Substances

-